Intelligent Bilayer Tablets for Enhanced Stability and Efficacy

Publication ID: 24-11857684_0008_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Intelligent Bilayer Tablets for Enhanced Stability and Efficacy,” Published Technical Disclosure No. 24-11857684_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857684_0008_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,684.

Summary of the Inventive Concept

The present inventive concept integrates oral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine with cutting-edge technologies like AI, IoT, blockchain, and novel materials to create a more powerful system for tracking stability, optimizing storage, and personalizing dosing.

Background and Problem Solved

The original patent disclosed bilayer tablets with improved dissolution properties, but it lacked a comprehensive system for ensuring the tablets' stability and efficacy throughout their lifecycle. This inventive concept addresses the limitations of the original patent by incorporating advanced technologies to monitor and predict degradation pathways, optimize storage conditions, and provide personalized dosing.

Detailed Description of the Inventive Concept

The system comprises a blockchain-based data storage platform for secure and transparent tracking of tablet stability and efficacy data. IoT-enabled sensors monitor environmental conditions, and an AI-powered predictive analytics module identifies potential degradation pathways. Additionally, machine learning algorithms analyze data from IoT-enabled sensors to predict optimal storage conditions, minimizing degradation. A novel, hydrophobic material is incorporated into the tablet composition to enhance stability in humid environments. Furthermore, a blockchain-based patient data storage platform, an AI-powered dosing algorithm, and a IoT-enabled dispenser facilitate personalized dosing. AI-powered image analysis detects changes in tablet morphology, correlating them with efficacy data from clinical trials.

Novelty and Inventive Step

The integration of AI, IoT, blockchain, and novel materials with the original bilayer tablet composition constitutes a new and non-obvious inventive concept. The synergistic combination of these technologies provides a comprehensive system for ensuring tablet stability and efficacy, which is not addressed by the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include using different AI algorithms, incorporating additional IoT-enabled sensors, or utilizing various blockchain platforms. Variations of the tablet composition could involve different ratios of acetylsalicylic acid to pseudoephedrine or the incorporation of other active pharmaceutical ingredients.

Potential Commercial Applications and Market

The intelligent bilayer tablets system has significant commercial potential in the pharmaceutical industry, particularly in the areas of cold and flu treatments. The system's ability to ensure tablet stability and efficacy, optimize storage conditions, and provide personalized dosing could lead to improved patient outcomes, reduced costs, and increased market share.

CPC Classifications

SectionClassGroup
A A61 A61K9/209
A A61 A61J3/10
A A61 A61K31/137
A A61 A61K31/616
A A61 A61K9/2009
A A61 A61K9/2018
A A61 A61K9/2054
A A61 A61K9/2059

Original Patent Information

Patent NumberUS 11,857,684
TitleOral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, methods of preparing and using thereof
Assignee(s)BAYER AKTIENGESELLSCHAFT